(Q44324002)

English

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

scientific article published in March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

J Lundin

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A Porwit-MacDonald

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

E D Rossmann

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

C Karlsson

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

P Edman

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M R Rezvany

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

E Kimby

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A Osterborg

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

H Mellstedt

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

484-490

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403258

0 references

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Current and developing chemotherapy for CLL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

21 January 2018

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

IMMUNE RECONSTITUTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403258

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403258

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44324002&oldid=2109444361"